Horizon Discovery Group will deploy its CRISPR-based screening platform to identify novel targets for rare genetic diseases in a new collaboration with Fulcrum Therapeutics. The programme will initially focus on genetic diseases where no effective treatment options currently exist. Horizon's CRISPR-based screening platform, sophisticated bioinformatics, and cell line libraries provide a novel and highly efficient way to examine the regulation of genes and their role in disease. In this collaboration, Horizon will apply its platform and extensive know-how to identify novel gene regulation targets for further exploration by Fulcrum for the development of next-generation therapies. The work will be engaged under a Full-time Equivalent (FTE) plus consumables model in a programme expected to run between five and seven months. Fulcrum has chosen Horizon as its preferred CRISPR-based screening platform service provider, and there is potential for further screens to identify targets for additional rare diseases after this initial programme.
-1.00p (-0.75%)delayed 13:21PM